BIDIL (hydralazine hydrochloride and isosorbide dinitrate) by R-Pharm US is established. Approved for heart failure, to prolong time to hospitalization for heart failure, to improve patient-reported functional status and 1 more indications. First approved in 2005.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
BIDIL is an oral combination tablet of hydralazine hydrochloride and isosorbide dinitrate, a nitrate vasodilator approved for heart failure. It works by dilating both arteries and veins through nitric oxide release, with hydralazine potentially mitigating nitrate tolerance. The drug is indicated to prolong time to hospitalization for heart failure and improve patient-reported functional status.
With LOE approaching and only $2M in Part D spending, BIDIL brand teams face significant headcount and budget reductions as the product exits market exclusivity.
established. Isosorbide dinitrate is a vasodilator affecting both arteries and veins. Its dilator properties result from the release of nitric oxide and the subsequent activation of guanylyl cyclase, and ultimate relaxation of vascular smooth muscle. Several well-controlled clinical trials have…
Nitrate Vasodilator
Worked on BIDIL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moBIDIL presents challenging career opportunities given its LOE approaching status and minimal job market linkage (0 identified positions). Working on this product offers limited growth potential and likely involves defending market share against superior competitors rather than driving innovation.